Podcasts about myelodysplastic syndromes

This week, Jonathan is joined by Eytan Stein, Chief of the Leukaemia Service and an Attending Physician at Memorial Sloan Kettering Cancer Center, New York, USA.  Timestamps:      (00:00)-Introduction  (01:05)-The current landscape of treatments  (02:26)-The promise and peril of differentiation therapy  (05:55)-Highlighting the most impactful clinical trials  (08:38)-Epigenetics and the future of targeted therapies  (10:40)-The BEAT AML master clinical trial  (12:57)-The latest research into IDH inhibitors  (16:10)-Therapies for splicing factor mutations  (19:29)-Reducing patient fear with education   (22:46)-Stein's three wishes for healthcare   

When Donna picked up a Hope Stone at her first AAMDSIF Patient and Family Conference, she couldn't foresee that she would be carrying it in her pocket on all challenging days. Listen here as Donna shares how she found hope while dealing with MDS, or Myelodysplastic Syndromes. For more content like this, please follow the AAMDSIF Podcast for Patients on Soundcloud, Apple Podcasts, Google Play, Spotify, or the website: https://www.aamds.org/education/podcast-episodes

Research continues to accelerate for myelodysplastic syndromes (MDS), giving hope to patients and their loved ones. In this episode, Dr.… The post There's Always Hope: Myelodysplastic Syndromes (MDS) first appeared on The Bloodline with LLS.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This week, Jonathan is joined by Dr Shahram Kordasti, Associate Professor in Applied Cancer Immunopathology at King's College London, UK. In this episode, Dr Kordasti discusses the immunobiology of Myelodysplastic syndrome and Aplastic anaemia, the role of CD4+ T cells in myeloid malignancies, and how cutting-edge computational tools are enhancing treatment strategies.   Timestamps:  (00:00)-Introduction  (01:23)-Hodgkin's lymphoma origin   (04:21)- Immunobiology of diseases  (08:55)-Plasticity of T cells   (13:42)-Computational biology and multiomics for patient stratification  (21:00)-Standardising immune monitoring  (25:41)- Pretreatment with systemic agents  (27:55)- Myeloproliferative neoplasms  (31:48)-Synthetic data generation   (36:22)-Exciting developments on the horizon   (39:16)-Three wishes for healthcare  

Featuring perspectives from Dr Harry Paul Erba, moderated by Dr Stephen “Fred” Divers CME information and select publications

Dr Harry Paul Erba shares his perspectives on the evolving therapeutic landscape for patients with leukemia and myelodysplastic syndromes, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/AON24).

Dr Harry Paul Erba shares his perspectives on the evolving therapeutic landscape for patients with leukemia and myelodysplastic syndromes.

Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen talked with Proactive's Stephen about the significant fast-track designation awarded to their cancer immunotherapy, bexmarilimab, by the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This milestone aligns with prior FDA acknowledgments, marking critical progress in addressing relapsed refractory Myelodysplastic Syndrome (r/r MDS). Faron also announced MHRA approval to expand its BEXMAB trial to UK sites. Jalkanen explained, “UK is like a second home for us,” emphasising the importance of extending treatment access to UK patients. He also detailed how the Innovation Passport streamlines regulatory interactions, rolling submissions, and early drug access opportunities. Looking ahead, Dr. Jalkanen shared that a confirmatory Phase 3 study is being planned for high-risk MDS patients globally, in collaboration with major regulatory authorities. The global trial underscores the company's dedication to delivering groundbreaking therapies to patients in need. For more insightful interviews, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and turn on notifications for updates! #faronpharmaceuticals #CancerImmunotherapy #Bexmarilimab #MDSResearch #BiotechInnovation #ClinicalTrials #MHRA #FDAApproval #GlobalHealthcare #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

This week Jonathan is joined by Joshua Zeidner, Associate Professor of Medicine, University of North Carolina School of Medicine, USA. Together, they discuss findings from recent research and treatment options for acute myeloid leukaemia and myelodysplastic syndrome. Timestamps:     (00:00)- Introduction    (01:57)- Joshua's love for the New York Giants  (04:28)- Treatment outcomes in IDH1 and IDH2-mutated acute myeloid leukaemia (AML)  (08:05)- Safety and efficacy of new agents in AML  (17:00)- Treatments for patients with AML with a TP53 mutation  (22:02)- Reliance on transfusion in myelodysplastic syndrome (MDS)  (25:44)- The time from research lab to bedside in drugs to treat AML and MDS  (30:50)- Joshua's three wishes for healthcare   (35:13)- Outro   

In this week's episode, we'll learn about the role of a platelet-specific glycoprotein receptor in abdominal aortic aneurysm formation, the influence of TP53 mutations on outcomes for patients with 5q-deleted myelodysplastic syndrome, and a rational combination treatment intended to produce more durable responses in patients with refractory B-cell acute lymphoblastic leukemia who are treated with CAR T-cell therapy.Featured Articles:Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic targetInfluence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletionA phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Azra Raza, Professor of Medicine and Director of the Myelodysplastic Syndrome (MDS) Center at Columbia University in New York, joins Jonathan Sackier to discuss her mission to shift the field of oncology, ensuring it focuses on eliminating the first cancer cell rather than chasing after the last.     Timestamps:   (00:00)-Introduction  (02:37)-Poetry  (08:50)-Raza's journey into oncology  (14:41)-Myelodysplastic syndrome and Raza's tissue bank  (21:16)-The First Cell    (28:18)-The cancer Questions Project  (38:20)-Goals for the future  (44:40)-The most pressing issues in cancer care  (48:14)-Financially incentivising early detection  (57:00)-3 Quarks Daily  (59:10)-Three wishes for healthcare   

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractory AML Phase I/II study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory FLT3-mutant AMLA retrospective comparison of abbreviated course 7+7 vs standard HMA plus venetoclax doublet in older/unfit patients with newly diagnosed AML Multisite randomized trial of a collaborative palliative and oncology care model for patients with AML and myelodysplastic syndromes (MDS) receiving nonintensive therapyFinal 5-year results from the phase II pivotal cohort of olutasidenib for IDH1-mutated AML Post hoc analyses of outcomes in patients with AML and MDS-related changes who received oral azacitidine maintenance therapy in the phase III QUAZAR AML-001 studyFirst-in-human phase I/II of the menin-MLL inhibitor DSP-5336 in patients with R/R acute leukemia: updated results from the dose escalation phase A phase Ib study of the menin-KMT2A inhibitor bleximenib in combination with venetoclax and azacitidine in R/R AML with alterations in KMT2A or NPM1 Program faculty:Eunice S. Wang, MDChief, Leukemia and Benign Hematology ServiceProfessor of OncologyRoswell Park Comprehensive Cancer CenterBuffalo, New YorkCourtney DiNardo, MD, MSCEProfessor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterHouston, TexasResources:To download the slides associated with this podcast discussion, please visit the program page:https://bit.ly/4bvJGij

In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the  EHA 2024 Congress including:COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low–, low- or intermediate-risk MDSReal-world dose-escalation and outcomes among patients with lower-risk MDS receiving luspatercept in clinical practicePhase II ASTREON trial―preliminary safety/efficacy of oral azacitidine in low-/intermediate, intermediate-risk, MDSPhase III IMerge: overall survival and transfusion independence with imetelstat in patients with low-risk or intermediate-1–risk MDS Phase III ENHANCE study of magrolimab plus azacitidine vs azacitidine plus placebo for higher-risk MDS Oral decitabine/cedazuridine plus venetoclax vs oral decitabine/cedazuridine alone in high-risk MDS: a propensity score analysis Program faculty:Courtney DiNardo, MD, MSCEProfessor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterHouston, TexasBrady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, IllinoisEunice S. Wang, MDChief, Leukemia and Benign Hematology ServiceProfessor of OncologyRoswell Park Comprehensive Cancer CenterBuffalo, New YorkResources:To download the slides associated with this podcast discussion, please visit the program page.

Recorded LIVE! At Johns Hopkins Internal Medicine Grand Rounds Step up your anemia game as we explore the causes and diagnostic approach for macrocytic anemia, what to do with a reticulocyte count, the differential diagnosis for hemolytic anemia, the significance of the direct antiglobulin test, and diagnosis and management pearls for autoimmune hemolytic anemia (AIHA) and myelodysplastic syndrome (MDS). Plus, common questions and concerns regarding folate supplementation and the use of bone marrow biopsies. We're joined by hematologist and pun enthusiast Dr. Rakhi Naik MD, MHS, @redcell_doc @hopkinsheme.  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Intro and Guest intro 05:53 Case 1: Elise - Macrocytic Anemia 14:59 Case 2: Jane - Hemolytic Anemia 23:24 Testing for Underlying Causes of Autoimmune Hemolytic Anemia 24:40 Association of Autoimmune Hemolytic Anemia with Lymphomas 25:10 Autoimmune Hemolytic Anemia: Diagnosis and Treatment 26:06 Management Approach for Autoimmune Hemolytic Anemia 27:30 Considerations for Outpatient Treatment of Autoimmune Hemolytic Anemia 28:18 Clotting Risk in Autoimmune Hemolytic Anemia 29:20 Treatment Options for Autoimmune Hemolytic Anemia 30:42 Long-Term Prognosis and Recurrence of Autoimmune Hemolytic Anemia 33:32 Diagnostic Challenges in Myelodysplastic Syndrome 35:00 Considerations for Folate Supplementation 36:24 Factors to Consider in the Management of Myelodysplastic Syndrome 39:30 When to Perform a Bone Marrow Biopsy in Myelodysplastic Syndrome 41:25 Shared Decision-Making in the Treatment of Myelodysplastic Syndrome Credits Writer and Producer: Matthew Watto MD, FACP Show Notes: Matthew Watto MD, FACP Cover Art and Infographic: Matthew Watto MD, FACP Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Fatima Syed MD, MSc Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Rakhi P. Naik MD, MHS Sponsor: Beginly Health Visit beginlyhealth.com/curbsiders job matching platform for every Physician and Advanced Practice Clinician, from training to practice. Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month. Sponsor: Babbel Get up to 60% off your Babbel subscription, for a limited time, at Babbel.com/CURB. 

In this episode, Peggy interviews Beth Ades, who shares her compelling journey after being diagnosed with Myelodysplastic Syndrome (MDS) in 2021. Beth's story begins with mysterious bruises on her legs, leading to a diagnosis that required immediate hospitalization and numerous tests. Despite a harrowing seven-month diagnostic process, Beth was eventually diagnosed with MDS and was told her only chance of survival was a bone marrow transplant.Beth recounts the emotional and physical challenges she faced, including a life-saving transplant from a 19-year-old donor in Germany. The connection between Beth and her donor has evolved into a meaningful relationship, showcasing the profound impact of such donations. Despite the difficulties, Beth's experience has been transformative, igniting a passion in her donor to pursue medicine and advocate for bone marrow registries.Post-transplant, Beth faced severe side effects such as mucositis, which she describes as far more than just mouth sores, but a condition affecting her entire gastrointestinal tract. Her proactive approach and close communication with her medical team were crucial in managing these issues.  This acute GVHD passed, but she still deals with chronic GVHD in her eyes.Beth also shares the wisdom imparted by her social worker about the challenging transition back to everyday life. The first hundred days post-transplant were particularly tough as she felt isolated from her family's ongoing life. However, the experience has given her a new perspective, emphasizing the importance of acknowledging and dealing with these emotional hurdles.The interview highlights the concept of paying it forward, which Beth embraced through organizing blood drives and bone marrow registry events. Her husband also became involved by signing up as a courier for the National Marrow Donor Program, (NMDP)  reflecting their deep commitment to giving back. There is also a tribute race car in the works, yet another way this family is raising awareness on and off the track. Beth's story underscores the collective effort required in the transplant journey, from medical professionals to supportive family and community members. Her reflections on gratitude, finding humor in difficult times, and the importance of small comforts, like warm blankets, offer valuable insights for others navigating similar experiences.Beth concludes with an inspiring note on the transformative power of her journey. She appreciates the profound changes it has brought to her life, stating she would choose her transplant life over her previous one despite the hardships. Her resilience and positivity are palpable, leaving listeners with a sense of hope and the importance of community support in overcoming life's toughest challenges.Resources:Beth's Bone Marrow Journey Facebook Page: https://www.facebook.com/profile.php?id=100077793195673NMDP (formerly Be The Match): https://bethematch.org/National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page:  https://www.facebook.com/nbmtLINKnbmtLINK YouTube Page can be found by clicking here.Thank you to our sponsors. This season is supported by a healthcare contribution from Sanofi  https://www.sanofi.com/ Follow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/

Featuring perspectives from Dr Richard M Stone, including the following topics:  • Introduction: ASH 2023 Update — Key Oral Presentations (0:00) • Case: A woman in her early 90s with dementia who presented with anemia and was diagnosed with low-risk myelodysplastic syndromes (MDS) with ring sideroblasts, now receiving luspatercept — Eric H Lee, MD, PhD (9:09) • Case: An African American woman in her early 60s with high-risk del(5q) MDS who receives oral decitabine/cedazuridine — Henna Malik, MD (26:05) • Case: A man in his late 60s with therapy-related acute myeloid leukemia (AML) with a FLT3-ITD mutation — Rebecca L Olin, MD, MSCE (34:49) • Case: A woman in her early 70s with PMH of inflammatory breast cancer diagnosed with FLT3-ITD AML who achieved a complete response (CR) with azacitidine/venetoclax, followed by gilteritinib maintenance for 2 years — Zanetta S Lamar, MD (40:43) • Case: A man in his mid 30s who presents with pathologic spinal fracture, is diagnosed with myeloid sarcoma and receives induction CLAG-M with CR followed by consolidation high-dose cytarabine — Anna Halpern, MD (43:56) • Case: A man in his mid 80s with MDS, complex cytogenetics and a TP53 mutation treated with azacitidine/venetoclax — Neil Morganstein, MD (46:40) • Case: A woman in her early 70s with newly diagnosed, poor-risk AML, ineligible for intensive chemotherapy (ECOG PS 2) who receives a hypomethylating agent/venetoclax — Amany R Keruakous, MD, MS (49:56) • Case: A man in his early 70s with relapsed AML (SRSF2, IDH1, ASXL1 mutations) after azacitidine/venetoclax, now receiving ivosidenib — Dr Halpern (55:23)   CME information and select publications  

Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes.

Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/MTPAMLMDS23/Part3).

Myelodysplastic Syndromes (MDS) is a group of diseases that have a variety of different treatments and outcomes. In this episode,… The post Improving Quality of Care for Myelodysplastic Syndromes (MDS) appeared first on The Bloodline with LLS.

Myelodysplastic Syndromes (MDS) is a group of diseases that have a variety of different treatments and outcomes. In this episode,… The post Improving Quality of Care for Myelodysplastic Syndromes (MDS) first appeared on The Bloodline with LLS.

Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents (HMA) for patients with myelodysplastic syndromes (MDS). In this interview, Dr. Zeidan further delves into his research and what it could mean for the future treatment landscape of MDS.

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!

Jonathan is joined by António Almeida, President of the European Hematology Association (EHA); and Professor and Director of the Clinical Haematology Service, Hospital da Luz, Lisbon, Portugal, to discuss his highlights since becoming EHA President. The pair cover the three pillars of EHA, the anticipated topics for the 2024 congress, and how Almeida has implemented a brand-new medical school, as well as much more.    Use the following timestamps to navigate the content in this episode: (00.00)-Introduction (01:55)-Almeida's new medical school (03:35)-EHA Master Class peer-based learning and modern medical education (09:00)-Presidential highlights  (11:50)-EHA's three pillars in the coming year (16:05)-EHA 2024 in Madrid (20:15)-Research in myeloproliferative and myelodysplastic syndromes (23:00)-Clinical trial updates in myelodysplastic syndromes and chronic myeloid leukaemia (26:50)-Changes over the course of Almeida's career (31:30)-Treatment advances on the horizon (32:50)-CRISPR to treat sickle cell disease and β-thalassaemia (36:30)-Three wishes for the future of healthcare 

In discussion with Dr. Amer Zeidan, covering how to treat myelodysplastic syndrome (MDS) in community settings. Dr. Zeidan is the director of early therapeutics research and associate professor of medicine at the Yale School of Medicine – Smilow Cancer Hospital. With Dr. Zeidan we covered MDS management in low-risk and high-risk patient population.   #PrecisionMedicine #Hematology #Cancer #Malignancy #MDS #BloodCancer #oncology #oncbrothers

Dr DiNardo discusses the the FDA approval of ivosidenib for patients with relapsed/refractory IDH1-mutant myelodysplastic syndromes, the unique mechanism of action of ivosidenib, and key efficacy and safety findings from the AG120-C-001 trial.

FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation

Featuring perspectives from Dr Gail J Roboz, including the following topics: Introduction (0:00) Case: A man in his early 50s presents with fatigue and pancytopenia; bone marrow shows myelodysplastic syndromes (MDS) with 11% blasts; normal FISH MDS panel; next-generation sequencing shows BCOR, RUNX1 and UTAF1 mutations; normal metaphase cytogenetics — Warren S Brenner, MD (10:12) Case: An African American woman in her early 60s with high-risk MDS receives oral decitabine/cedazuridine — Henna Malik, MD (16:39) Case: A woman in her early 70s with anemia and low-grade MDS with ring sideroblasts experiences a poor response to erythropoietin and is now on luspatercept — Neil Morganstein, MD (22:15) Case: A woman in her early 60s with newly diagnosed acute myeloid leukemia (AML) and a FLT3-ITD mutation receives 7 + 3 induction with midostaurin induction, consolidation, allogeneic transplant and maintenance — Amany R Keruakous, MD, MS (35:23) Case: A man in his mid 60s with AML and an IDH1 mutation receives venetoclax/azacitidine/ivosidenib — Rebecca L Olin, MD, MSCE (53:23) Case: A woman in her late 30s with refractory leiomyosarcoma develops anthracycline-related secondary AML with an IDH2 mutation and is unable to obtain foundation funding assistance for enasidenib copays — Eric H Lee, MD, PhD (56:48) CME information and select publications

Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (http://www.ResearchToPractice.com/MTPAMLMDS23/Part2).

Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes.

Featuring perspectives from Dr Naval Daver, including the following topics: Introduction: Biology, Classification, p53, Magrolimab (0:00) Case: A man in his early 70s with acute myeloid leukemia (AML) with a TP53 mutation, myelodysplastic syndromes (MDS)-related changes and complex cytogenetics who received CPX-351receives azacitidine/venetoclax and is now in palliative care — Anna Halpern, MD (9:06) Case: A woman in her late 50s with multiple comorbidities and FLT3-ITD-positive AML who experienced disease progression on azacitidine/venetoclax now receives gilteritinib — Bhavana (Tina) Bhatnagar, DO (17:01) Case: A woman in her early 70s with AML with FLT3-ITD and IDH1 mutations receives a hypomethylating agent with ivosidenib — Amany R Keruakous, MD, MS (29:10) Case: A man in his early 60s with newly diagnosed MDS with ring sideroblasts receives oral decitabine/cedazuridine — Khuda Dad Khan, MD, PhD (33:54) Case: A man in his mid 60s presents with copper deficiency and ring sideroblasts; genetic analysis reveals SF3B1 and DNMT3A mutations — Rachel J Cook, MD (42:25) Case: A woman in her early 70s with a history of extensively treated follicular lymphoma develops AML and receives CPX-351 — Ranju Gupta, MD (46:05) Case: A woman in her late 70s with newly diagnosed AML receives decitabine/venetoclax with concurrent voriconazole — Rebecca L Olin, MD, MSCE (51:05) Case: A woman in her late 90s is diagnosed with multiple myeloma and del(5q) MDS — Erik Rupard, MD (54:26) Journal Club with Dr Daver (57:28) CME information and select publications

Dr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes. CME information and select publications here (https://www.researchtopractice.com/MTPAMLMDS23/Part1)

Dr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes.

This episode covers myelodysplastic syndrome.Written notes can be found at https://zerotofinals.com/medicine/haematology/myelodysplasticsyndrome/ or in the haematology section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.

In this episode, join us as we sit down with Theresa McCarter, a devoted family member to delve into the world of Myelodysplastic Syndromes (MDS) and the arduous one treads after receiving a life-altering diagnosis.

Can an oral medication replace metabolic surgery? Find out about this and more in today's PV Roundup podcast.

Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman, including the following topics: Introduction (00:00) Biology of Acute Myeloid Leukemia/Myelodysplastic Syndromes (3:14) Assessment of Risk Status (14:17) Oral Hypomethylating Agents (HMAs) (22:24) HMA/Venetoclax; Other Combinations (31:26) Magrolimab/TP53 (45:12) CME information and select publications  

Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes — Faculty Presentation 1: Current management of higher-risk myelodysplastic syndromes (MDS) — Guillermo Garcia-Manero, MD CME information and select publications  

Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes — Faculty Presentation 2: Future directions in the management of higher-risk MDS  — Dr David Sallman CME information and select publications

Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman. CME information and select publications here (https://www.researchtopractice.com/InsidetheIssue2023/MDS)

Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman, moderated by Dr Neil Love.

Featuring perspectives from Ms Ilene Galinsky, Dr Ruben A Mesa, Dr Daniel A Pollyea, Dr Richard M Stone and Dr Sara M Tinsley-Vance, including the following topics: Introduction (0:00) Overview of Myeloproliferative Neoplasms and Myelofibrosis (MF) — Impact of Ruxolitinib (5:28) New Agents in MF — Fedratinib, Momelotinib, Pacritinib (31:13) Myelodysplastic Syndromes — Management of Low- and High-Risk Disease (52:59) Overview of Acute Myeloid Leukemia (AML) (1:15:18) Targeted Therapy for AML (1:26:02) NCPD information and select publications

Featuring perspectives from Dr Uma Borate and Prof Andrew Wei, including the following topics: Introduction (0:00) Acute Myeloid Leukemia (AML): Key Papers and Presentations (3:30) Myelodysplastic Syndromes (MDS): Key Papers and Presentations (36:32) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes — Faculty Presentation 2: Myelodysplastic Syndromes — Dr Uma Borate, MD, MS CME information and select publications